HER2/neu-specific antibodies and methods of using same
This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
1. A method of treating a HER2/neu-expressing cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an antibody that binds human HER2/neu and comprises:
(A) an immunoglobulin light chain comprising an amino acid sequence of SEQ ID NO: 2; and
(B) an immunoglobulin heavy chain comprising an amino acid sequence of SEQ ID NO: 11, wherein said antibody is administered by intravenous infusion.
2. The method of claim 1 , comprising the further step of administering a second therapeutic agent simultaneously or sequentially with said antibody.
3. The method of claim 2 , wherein said second therapeutic agent and said antibody are administered no more than 96 hours apart.
4. The method of claim 2 , wherein said second therapeutic agent is selected from the group consisting of an anti-angiogenic agent, an anti-neoplastic agent, a chemotherapeutic agent, and a cytotoxic agent.
5. The method of claim 4 , wherein said chemotherapeutic agent is cisplatin, doxorubicin or paclitaxel.
6. The method of claim 2 , wherein said second therapeutic agent is selected from the group consisting of an anti-mitotic agent, a hormone therapy agent, and an aromatase inhibitor.
7. A method of treating a HER2/neu-expressing cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising an antibody that binds human HER2/neu and comprises:
(A) an immunoglobulin light chain comprising an amino acid sequence of SEQ ID NO: 2; and
(B) an immunoglobulin heavy chain comprising an amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 11, or SEQ ID NO: 13; and
(C) a pharmaceutically acceptable carrier and/or an excipient; and
wherein said administration is by intravenous infusion.
8. The method of claim 7 , further comprising the steps of:
(A) providing said pharmaceutical composition as a sterile liquid in a hermetically sealed container; and
(B) extracting said pharmaceutical composition from said hermetically sealed container prior to said administering step.
9. The method of claim 7 , comprising the further step of administering a second therapeutic agent simultaneously or sequentially with said antibody.
10. The method of claim 8 , comprising the further step of administering a second therapeutic agent simultaneously or sequentially with said antibody.
11. The method of claim 9 , wherein said second therapeutic agent and said antibody are administered no more than 96 hours apart.
12. The method of claim 10 , wherein said second therapeutic agent and said antibody are administered no more than 96 hours apart.
13. The method of claim 9 , wherein said second therapeutic agent is selected from the group consisting of an anti-angiogenic agent, an anti-neoplastic agent, a chemotherapeutic agent, and a cytotoxic agent.
14. The method of claim 10 , wherein said second therapeutic agent is selected from the group consisting of an anti-angiogenic agent, an anti-neoplastic agent, a chemotherapeutic agent, and a cytotoxic agent.
15. The method of claim 13 , wherein said chemotherapeutic agent is cisplatin, doxorubicin or paclitaxel.
16. The method of claim 14 , wherein said chemotherapeutic agent is cisplatin, doxorubicin or paclitaxel.
17. The method of claim 9 , wherein said second therapeutic agent is selected from the group consisting of an anti-mitotic agent, a hormone therapy agent, and an aromatase inhibitor.
18. The method of claim 10 , wherein said second therapeutic agent is selected from the group consisting of an anti-mitotic agent, a hormone therapy agent, and an aromatase inhibitor.
19. The method of claim 1 , wherein said HER2/neu-expressing cancer is breast cancer, prostate cancer, uterine cancer, ovarian cancer, colon cancer, endometrial cancer, adrenal carcinoma, or non-small cell lung cancer.
20. The method of claim 7 , wherein said HER2/neu-expressing cancer is breast cancer, prostate cancer, uterine cancer, ovarian cancer, colon cancer, endometrial cancer, adrenal carcinoma, or non-small cell lung cancer.
21. The method of claim 8 , wherein said HER2/neu-expressing cancer is breast cancer, prostate cancer, uterine cancer, ovarian cancer, colon cancer, endometrial cancer, adrenal carcinoma, or non-small cell lung cancer.